ClinicalTrials.gg
CompletedNCT06475547Updated Oct 15, 2026

Inflammation and Postoperative Atrial Fibrillation in Cardiac Surgery

An observational study in Atrial Fibrillation and Inflammation, sponsored by Odense University Hospital. Completed at 1 site in Denmark. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Odense University Hospital · Observational

How we know

Updated Oct 15, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
85
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Atrial Fibrillation by Odense University Hospital — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Odense University Hospital.

Started
2022
with 1 other
Observational
4 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Atrial Fibrillation by Odense University Hospital, this one is one of 2 that started in 2022, is one of 4 observational ones, and was the 10th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 10 studies in Atrial Fibrillation by Odense University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atrial Fibrillation by Odense University Hospital, or all of them as a file.
02

Study summary

Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, marked by an irregular and rapid heart rate, and associated with increased morbidity, longer hospital stays, and higher costs. Its complex pathophysiology involves atrial remodeling, inflammation, and autonomic dysregulation. Surgical trauma and cardiopulmonary bypass trigger an inflammatory response, releasing cytokines. Epicardial fat around the heart secretes pro-inflammatory cytokines, and its increased thickness is linked to higher inflammation and atrial fibrillation. This study uses RNA sequencing (RNA-seq) to profile gene expression in epicardial fat, identifying key genes involved in inflammation and metabolism. By comparing patients with and without POAF, RNA-seq reveals differentially expressed genes associated with postoperative atrial fibrillation.

Read the detailed description

Postoperative Atrial Fibrillation (POAF) after Cardiac Surgery Postoperative atrial fibrillation is a common complication following cardiac surgery, characterized by irregular and often rapid heart rate. It is associated with increased morbidity, prolonged hospital stays, and higher healthcare costs. The pathophysiology of POAF is complex and multifactorial, involving atrial structural and electrical remodeling, inflammation, and autonomic dysregulation.

Inflammation and Epicardial Fat Inflammation plays a significant role in the development of POAF. Surgical trauma and cardiopulmonary bypass trigger a systemic inflammatory response, releasing cytokines and other inflammatory mediators. Epicardial fat, the visceral fat depot around the heart, is an active endocrine organ secreting pro-inflammatory cytokines and adipokines. Increased epicardial fat thickness is associated with higher levels of inflammation and has been implicated in the pathogenesis of atrial fibrillation.

RNA isolation and sequencing RNA sequencing (RNA-seq) can be used to investigate gene expression in epicardial fat in several impactful ways. RNA-seq can profile gene expression to identify active genes in epicardial fat and their expression levels, revealing key genes involved in inflammation and metabolism. By comparing gene expression between groups, such as patients with and without POAF, RNA-seq can identify differentially expressed genes associated with atrial fibrillation.

RNA-seq analyses The RNA sequencing data files were aligned to the hg38 reference genome using the Spliced Transcripts Alignment to a Reference (STAR) aligner and read counts in genes were quantified. The resulting data matrix with unnormalized counts was loaded into RStudio together with patient metadata information (e.g., age, gender, BMI, smoking). Differential expression analyses were conducted with DESeq2 using adjustment for different variables, including type of tissue, age of patients, gender, and BMI.

Hypothesis The hypothesis that POAF may be influenced by pre-existing inflammation in epicardial fat, in addition to the inflammation caused by surgical trauma.

Objective:

To compare inflammatory gene expression in epicardial fat between patients who develop POAF and those who do not after elective cardiac surgery.

Study Design:

A prospective cohort study including patients undergoing first-time elective cardiac surgery.

Participants:

Inclusion criteria: Patients undergoing first-time elective cardiac surgery. Exclusion criteria: Patients with previous cardiac surgeries or emergency surgeries.

Groups:

POAF Group: Patients who develop POAF. Non-POAF Group: Patients who do not develop POAF.

Sample Collection:

Epicardial fat samples will be collected during the time of surgery.

RNA Isolation and Sequencing:

Homogenize adipose tissue in TRIzol using ceramic beads (Fastprep 24, MPBio). Purify RNA using EconoSpin columns (Epoch). Prepare RNA libraries with NEBNext Ultra II RNA Library Prep Kit for Illumina. Perform paired-end sequencing on the NovaSeq 6000 platform (Illumina).

Data Analysis:

Align RNA-seq data to the hg38 genome using STAR aligner. Quantify gene counts and perform differential expression analysis using DESeq2. Adjust for variables such as tissue type, age, gender, and BMI.

Outcome Measures:

Compare inflammatory gene expression profiles between POAF and Non-POAF groups at the time of surgery.

03

Conditions studied

  • Atrial Fibrillation
  • Inflammation
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients undergoing cardiac surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18

Exclusion criteria

Exclusion Criteria:

  • Incompetent individuals
  • General poor health condition at the time of inclusion
  • Reoperation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
85 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • POAF

    Patients who develop postoperative atrial fibrillation.

    Other: Descriptive

  • Non-POAF

    Patients who do not develop postoperative atrial fibrillation.

Interventions

  • OtherDescriptive

    This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.

06

What researchers measure

Primary outcomes

  1. Differential expression of genes

    The primary endpoint of this study is to identify differentially expressed (DE) genes using RNA sequencing (RNA-seq) data. Post-sequencing, we will utilize the default settings and statistical methods provided by DESeq2 to determining statistically significant differences in gene expression between the experimental conditions. The gene signal is measured in normalized counts per kilobase or in Fragments Per Kilobase of transcript per Million mapped reads.

    Time frame: The sample is taken at the time of surgery.

07

Study locations

1 site
  • Odense University Hospital, Cardiac Surgery Department
    Odense, 5000, Denmark
08

References and documents

Publications

  • Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013 Jan 1;29(1):15-21. doi: 10.1093/bioinformatics/bts635. Epub 2012 Oct 25. PubMed 23104886 ↗
  • Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed 25516281 ↗
  • Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017 May 1;38(17):1294-1302. doi: 10.1093/eurheartj/ehw045. PubMed 26935271 ↗

Individual participant data

Plan to share: Yes — Data will be available in anonymized form in accordance with GDPR upon reasonable request. Data will be shared with researchers whose proposed use has been approved, primarily for replication of our results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: TBA

Access criteria: To request access, contact Lytfi.Krasniqi@rsyd.dk. A signed data access agreement, compliant with regional legislation and data authority requirements, is required prior to data release.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2026, 48 months.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 48 months is close to that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2027 → Jan 2026 and completion Jan 2027 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jun 26, 2024
StartActual
Jan 1, 2022
Primary completionActual
Jan 1, 2026was Jan 2027
CompletionActual
Jan 1, 2026was Jan 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Primary completion
Jan 1, 2027→Jan 1, 2026 (actual)
Oct 15, 2026
Study completion
Jan 1, 2027→Jan 1, 2026 (actual)
Oct 15, 2026
Enrollment
100 (estimated)→85 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Completed
    Primary completion Jan 1, 2027→Jan 1, 2026 (now actual)
    Study completion Jan 1, 2027→Jan 1, 2026 (now actual)
    Enrollment 100 (estimated)→85 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06475547
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Jan 1, 2022
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026
Last update
Oct 15, 2026

Study contacts

Lytfi Krasniqi, MD
principal investigator · Odense University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion